A pathology tool created at Yale harnesses barcode technology and shows potential for use in cancer diagnoses. The technology, Patho-DBiT (pathology-compatible deterministic barcoding in tissue), was discussed in a study published Sept. 30 in the journal Cell.Â
Xcell Biosciences Inc., an instrumentation company focused on cell and gene therapy applications, has expanded its collaboration with AmplifyBio, a rapidly growing contract development and manufacturing organization, through the installation of a new AVATAR Foundry system as part of Xcellbio’s beta access program.Â
AMG 193, an MTA-cooperative PRMT5 inhibitor, demonstrated responses across patients with MTAP-deleted solid tumors, as well as an acceptable safety profile, according to first-in-human results of a dose-exploration/dose-expansion phase I study (NCT05094336) that were presented at the 2024 ESMO Congress.
The phase III comparative clinical trial for the investigational Perjeta (pertuzumab) biosimilar HLX11 met the primary endpoint of total pathological complete response rate.Â
A new study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center has demonstrated a new, non-invasive imaging technique can accurately detect clear-cell renal cell carcinoma, the most common form of kidney cancer.
Vulnerable patients facing social, environmental, and economic disadvantages often experience worse cancer outcomes than other groups. Some of these disparities may be reduced by increasing access to hospitals accredited by the American College of Surgeons Commission on Cancer, according to a study published in the Journal of the American College of Surgeons.
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have developed the largest collection of sarcoma patient-derived organoids to date that can help improve the understanding of the disease and better identify therapies that are most likely to work for each individual patient.Â
Positive results from the NIAGARA phase III trial showed Imfinzi (durvalumab)in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival and the key secondary endpoint of overall survival versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer.Â
Updated results from the HIMALAYA phase III trial showed AstraZeneca’s Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) demonstrated a sustained, clinically meaningful overall survival benefit at five years for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy and were not eligible for localized treatment.
Results from a large phase III clinical trial show that treatment with Keytruda (pembrolizumab) may nearly double the length of time people with high-risk muscle-invasive bladder cancer are cancer-free following surgical removal of the bladder.Â